Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix K-H Chun

Showing results (1-10 of 608) with videos related to

Pageof 61
Sort By:
European Urology|May 1, 2007
Editorial comment on: Prostate cancer characteristics in a multiracial communityFelix K-H Chun
European Urology|May 6, 2008
Editorial comment on: 11C-choline-positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomogramsFelix K-H Chun
European Urology|April 12, 2008
Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA valuesFelix K-H Chun, Alberto Briganti
Aktuelle Urologie|April 15, 2016
[Not Available]Luis A Kluth, Felix K-H Chun
European Urology|August 9, 2022
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol 2022;81:576-85Mike Wenzel, Felix K-H Chun, Andreas Becker
Chinese Clinical Oncology|October 11, 2023
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?Benedikt Hoeh, Felix K H Chun, Philipp Mandel
The Journal of Urology|January 18, 2017
Editorial CommentPhilipp Gild, Felix K H Chun, Andreas Becker
European Urology Focus|February 22, 2023
Reply to Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, et al's Letter to the Editor re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007Benedikt Hoeh, Felix K H Chun, Philipp Mandel
Advances in Experimental Medicine and Biology|November 5, 2015
Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical AspectsMarianne Schmid, Jens Hansen, Felix K-H Chun
World Journal of Urology|July 5, 2014
Prostate imaging--the future is now: current concepts and future potentialsFelix K-H Chun, Thomas R W Herrmann
Pageof 61

Showing results (1-10 of 608) with videos related to

Sort By:
Pageof 61
European Urology|May 1, 2007
Editorial comment on: Prostate cancer characteristics in a multiracial communityFelix K-H Chun
European Urology|May 6, 2008
Editorial comment on: 11C-choline-positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomogramsFelix K-H Chun
European Urology|April 12, 2008
Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA valuesFelix K-H Chun, Alberto Briganti
Aktuelle Urologie|April 15, 2016
[Not Available]Luis A Kluth, Felix K-H Chun
European Urology|August 9, 2022
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol 2022;81:576-85Mike Wenzel, Felix K-H Chun, Andreas Becker
Chinese Clinical Oncology|October 11, 2023
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?Benedikt Hoeh, Felix K H Chun, Philipp Mandel
The Journal of Urology|January 18, 2017
Editorial CommentPhilipp Gild, Felix K H Chun, Andreas Becker
European Urology Focus|February 22, 2023
Reply to Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, et al's Letter to the Editor re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007Benedikt Hoeh, Felix K H Chun, Philipp Mandel
Advances in Experimental Medicine and Biology|November 5, 2015
Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical AspectsMarianne Schmid, Jens Hansen, Felix K-H Chun
World Journal of Urology|July 5, 2014
Prostate imaging--the future is now: current concepts and future potentialsFelix K-H Chun, Thomas R W Herrmann
Pageof 61